Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD  by Abrahams, Roger et al.
Respiratory Medicine (2013) 107, 854e862Available online at www.sciencedirect.com
journal homepage: www.elsevier .com/locate /rmedSafety and efficacy of the once-daily
anticholinergic BEA2180 compared with
tiotropium in patients with COPDRoger Abrahams a, Petra Moroni-Zentgraf b,*, Joe Ramsdell c,
Hendrik Schmidt b, Elizabeth Joseph d, Jill Karpel eaMorgantown Pulmonary Associates, Morgantown, 1265 Pineview Drive, Morgantown, WV 26505, USA
bBoehringer Ingelheim Pharma GmbH & Co KG, Binger Strabe 173, D-55216 Ingelheim am Rhein,
Germany
cUniversity of California San Diego Health Sciences Clinical and Translational Research Institute, 200
West Arbor Drive MC, 8415, San Diego, CA 92013-8415, USA
dBoehringer Ingelheim Pharmaceuticals Inc, 900 Ridgebury Road, Ridgefield, CT 06877, USA
eNorth Shore Medical Arts, LLP, 295 Community Drive, Great Neck, NY 11021, USAReceived 6 December 2012; accepted 11 February 2013
Available online 13 March 2013KEYWORDS
BEA2180;
Tiotropium;
Respimat;
Chronic obstructive
pulmonary disease;
Exacerbations;
Transition Dyspnoea
Index* Corresponding author. Tel.: þ49 6
E-mail address: petra.moroni-zent
0954-6111/$ - see front matter ª 201
http://dx.doi.org/10.1016/j.rmed.20Summary
Background: To determine the safety and efficacy of BEA2180, an anticholinergic agent in pa-
tients with chronic obstructive pulmonary disease (COPD).
Methods: Smokers or ex-smokers 40 years with COPD and a postbronchodilator forced expi-
ratory volume in 1 s (FEV1) <80% predicted and FEV1/forced vital capacity 70% participated in
this multinational, randomised, double-blind, parallel study. Patients received BEA2180 (50,
100 or 200 mg), tiotropium (5 mg) or placebo once daily via Respimat Soft Mist. The primary
endpoint was trough FEV1 after 24 weeks. Secondary endpoints included Transition Dyspnoea
Index (TDI) focal score, St George’s Respiratory Questionnaire (SGRQ) total score, exacerba-
tions and adverse events.
Results: Patients (nZ 2080, 64.5% male) had a mean age of 64.2 years and a baseline FEV1 of
1.2 L. Trough FEV1 at 24 weeks with all BEA2180 doses (0.044e0.087 L) and tiotropium 5 mg
(0.092 L) was significantly higher (p < 0.0001) than placebo (0.034 L) and BEA2180
(200 mg) was noninferior to tiotropium. Mean TDI focal scores were higher with BEA2180
(1.43e1.48) or tiotropium (1.46) versus placebo (0.94; p  0.01 for all). Mean SGRQ total scores
also improved with BEA2180 (40.1e40.7) or tiotropium (39.5) compared with placebo (43.0,
p < 0.01 for all). COPD exacerbation rates were reduced for all active treatments, reaching
statistical significance for BEA2180 (50 and 200 mg) (p < 0.05, for both).132 77 7301; fax: þ49 6132 72 7301.
graf@boehringer-ingelheim.com (P. Moroni-Zentgraf).
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BEA2180 versus placebo and tiotropium via Respimat SMI 855Conclusion: All study doses of BEA2180 improved lung function, reduced symptoms and exac-
erbations, and improved health status in COPD; all treatments were well tolerated.
Clinical trial identifier: NCT00528996.
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The natural history of chronic obstructive pulmonary dis-
ease (COPD) is characterised by a progressive loss of lung
function that is accompanied by worsening dyspnoea, ex-
acerbations, potentially serious systemic consequences and
comorbidity.5,6 Not only does COPD lead to reduced phys-
ical activity and quality of life, but it also reduces life
expectancy22e24,30; COPD is expected to become the third
leading cause of death worldwide by 2030.31 Current
treatment guidelines recommend short-acting bronchodi-
lators to manage intermittent symptoms in mild forms of
the disease and advocate maintenance therapy with long-
acting bronchodilators (anticholinergics, long-acting b2-
adrenergic agonists [LABAs]) in moderate-to-severe COPD
or combinations of long-acting bronchodilators and inhaled
corticosteroids (ICS) for those with exacerbations.8
Tiotropium is a once-daily, long-acting anticholinergic
bronchodilator available for the management of COPD
symptoms.16 Long-term data have demonstrated that
treatment with tiotropium leads to improved lung function,
reduced exacerbations and increased quality of life in pa-
tients with COPD compared with placebo.3,27,29 A 5-mg dose
delivered once-daily via the Respimat Soft Mist Inhaler
(SMI) was recently shown to be noninferior to an 18-mg dose
using the HandiHaler system.28 Clinical studies have sup-
ported the approval of 5 mg of once-daily inhaled tio-
tropium as the standard regimen for the management of
COPD.3 In a recent, 1-year study with exacerbations as the
primary endpoint, a statistically nonsignificant trend of
increased all-cause mortality was observed with tiotropium
5 mg SMI.3 This led to the initiation of the currently on-going
TIOSPIR study, a large-scale, prospective, randomised
trial, comparing tiotropium SMI 5 mg, 2.5 mg and Handi-
Haler 18 mg in >17,000 patients. The result of a pooled
analysis of all studies with tiotropium 5 mg SMI, including
vital status follow up, showing a numerical trend of
increased all-cause mortality is described in the local pre-
scribing information. BEA2180 is a once-daily, inhaled,
long-acting anticholinergic bronchodilator also delivered
via Respimat SMI. Although there are minor differences in
the properties of BEA2180 based on animal/preclinical
data, there were no significant differences in efficacy and
safety, including onset of action, in late-stage develop-
ment. A previous dose-ranging study provided a proof-of-
concept 24-h duration of action for BEA2180 delivered via
the Respimat SMI in patients with moderate-to-severe
COPD.14 BEA2180 Respimat SMI (10, 20, 50, 100 and
200 mg), tiotropium Respimat SMI (5 mg) and placebo were
administered once daily over 4 weeks of treatment. The
primary endpoint (trough forced expiratory volume in 1 s
[FEV1]) was reached with BEA2180 (50, 100 and 200 mg),
with trough FEV1, D Z e0.087, e0.101 and e0.147 L,
respectively, compared with placebo (p < 0.05 for all) andnumerically higher than tiotropium (e0.100) with 100 and
200-mg doses. The safety profile for BEA2180 was similar to
tiotropium. The most common adverse events (AEs) re-
ported were nasopharyngitis and COPD exacerbations, as
expected for this patient population and study period.
The primary objective of the current study (Clinical Trial
number: NCT00528996) was to compare the long-term bron-
chodilator efficacy and safety of three once-daily doses (50,
100 and 200 mg) of BEA2180 delivered by the Respimat SMI
with placebo and the marketed and approved tiotropium
Respimat SMI 5 mg3 for 24 weeks in patients with COPD.
Methods
Study design
We conducted a 24-week, multiple-dose, multicentre,
multinational, randomised, double-blind, parallel-group
study. Following an initial screening phase and 2-week
baseline period to ensure clinical stability, patients were
randomly assigned to BEA2180 Respimat SMI (50, 100 or
200 mg), tiotropium Respimat SMI (5 mg) or placebo with
clinic visits occurring at weeks 1, 2, 4, 8, 12, 18 and 24.
Rescue medication could be administered at any time
during the study; open-label salbutamol was provided at
visits 1 and 9 as required and patients were encouraged to
document its use. If salbutamol was used during a test day
visit, the patient did not complete the remainder of the
pulmonary function testing (PFT) on that day. Temporary in-
creases in the dose or addition of oral steroids was allowed
during the study period, however PFTs did not occur within
5 days of either. The use of antibiotics was not restricted. The
following medications were allowed as long as they had been
administered in stable doses over 6 weeks prior to the study:
oral corticosteroids (10 mg daily); inhaled LABAs, oral ICS,
theophylline preparations and mucolytic agents not contain-
ing bronchodilators. Short-acting anticholinergic drugs were
allowed during the 2-week baseline period and the 3-week
follow-up period. The use of short-acting beta adrenergic
therapies other than salbutamol, anticholinergic drugs other
than the study drug and their combinations was prohibited.
The study was conducted in accordance with the pro-
visions of the Declaration of Helsinki (1996) and Good
Clinical Practice guidelines.18 The protocol was approved
by the ethics committee at each study centre, and all pa-
tients provided written informed consent before any study
procedure was performed.
Patients
Patients were recruited at 178 investigational centres,
based in 10 countries. Male and female smokers or ex-
smokers with a smoking history of more than 10 pack-years
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included in the study. All patients were diagnosedwith COPD
and demonstrated postbronchodilator FEV1 <80% pre-
dicted20 with FEV1/forced vital capacity (FVC) 70%. Pa-
tients were excluded if they had: never smoked or smoked
<10 pack-years; a history of asthma; been treated for a
myocardial infarction within the past year; unstable or life-
threatening cardiac arrhythmia (or associated hospital-
isations); been hospitalised for heart failure within the past
3 years; regular use of daytime oxygen therapy and the
inability to abstain from the use of oxygen therapy during
test days; thoracotomywith pulmonary resection and/or the
presence of a significant disease other than COPD that could
preclude participation in the study or interfere with the
study results. The randomisation of patients with any res-
piratory infection or COPD exacerbation in the 6 weeks prior
to screening or during the baseline period was postponed.
Further details of patients’ inclusion and exclusion criteria
can be found in the online supplement.Assessments
Spirometry was performed according to American Thoracic
Society guidelines.17 Qualifying PFTs (FEV1 and FVC) were
conducted at the screening visit. At weeks 3, 4, 6 and 8,
PFTs (FEV1 and FVC) were only performed for the trough
(pre-dosing) measurement. At weeks 2, 5, 7 and 9, PFTs
(FEV1 and FVC) were performed prior to dosing (trough) and
at 15, 30 and 60 min, 2 and 3 h after inhalation of study
medication. Prebronchodilator and postbronchodilator re-
sponses were recorded prior to and 30 min after the
administration of salbutamol (400 mg). Additional details of
spirometry can be found in the online supplement. Trough
FEV1 was defined as the mean of two measurements, at 40
and 15 min time points at the end of the 24-h dosing in-
terval, prior to drug administration in the morning. Trough
FEV1 response was defined as the change from baseline in
trough FEV1 defined as the mean of the pre-treatment FEV1
values measured at randomisation prior to administration
of the first dose of study medication. No significant
treatment-by-subgroup interaction was observed between
subgroups in terms of disease severity at baseline, LABA or
ICS usage. The Mahler BDI15 was performed at the ran-
domisation visit, whereas the Mahler TDI was completed at
treatment visits starting with week 5. The TDI was also
administered at weeks 7, 9 and 10. The BDI/TDI question-
naires were administered by physicians, nurses, respiratory
therapists or cardiopulmonary technicians. The SGRQ13 was
administered at weeks 2, 5, 7, 9 and 10, prior to PFTs at all
visits and after the Mahler BDI/TDI questionnaires. Reports
of any AEs were collected at each visit.
An exacerbation was defined as a complex of lower
respiratory events/symptoms (increased or new onset)
related to the underlying COPD, with a duration of 3 days or
more, requiring a change in treatment where a complex of
lower respiratory events/symptoms meant at least two of
the following: Shortness of breath; sputum production
(volume); occurrence of purulent sputum; cough;
wheezing; chest tightness.
Exacerbations were recorded as mild when there was a
significant change of prescribed respiratory medication(i.e. bronchodilators, including theophylline). Exacerba-
tions were classified as moderate or severe when the
required change in treatment also included the prescription
of antibiotics and/or systemic steroids. COPD exacerbations
were captured as AEs and recorded on the AE electronic
case report form.
Inhalers
The Respimat inhaler was used for all medications. There
were no differences in the resulting in vitro aerodynamic
particle size distribution for all medications, irrespective of
strength and compound.
Statistical analyses
Using previous calculations (unpublished data); the stan-
dard deviation (SD) for trough FEV1 was estimated at
0.215 L. On this basis, a sample size of approximately 1950
randomised patients (390 per treatment group) was
deemed sufficiently sensitive to detect a difference of
0.05 L between all BEA2180 doses and tiotropium at the
0.025 level of significance (one-sided) with 90% power. The
noninferiority margin for FEV1 was chosen to be 0.05 L.
Further details on the statistical hypotheses and testing
procedures can be found in the online supplement.
All analyses, except where stated otherwise, were per-
formed using data from all patients in the full analysis set.
This consisted, individually for each endpoint, of all rand-
omised patients with baseline data (pretreatment at the
end of the 2-week baseline) and at least one adequate
trough PFT following at least 5 days of randomised treat-
ment. All spirometry endpoints (trough, area under the
curve from 0 to 3 h [AUC03h], peak and measurements at
individual time points) physician’s global evaluation, peak
expiratory flow rate measurements and rescue medication
use were summarised using analysis of covariance (ANCOVA)
with terms for baseline (trough, AUC03h or peak), centre
and treatment. The baseline was used as a linear covariate.
A separate ANCOVA was performed for each time point (test
day, week of diary data or time point within test day).
Exacerbation analysis was performed on the treated set
presented as KaplaneMeier estimates for COPD exacerba-
tions by treatment arm. Patients with a TDI focal score of
one or more were considered to be responders. A change of
four units in the SGRQ total score was considered to be
clinically meaningful and patients with a reduction of four
units were considered responders. Both SGRQ and TDI focal
score data were analysed using ANCOVA. All safety data
were displayed and analysed using descriptive statistical
methods. Full details of statistical analyses can be found in
the online supplement.
Results
Study population
All randomised patients (n Z 2080) received at least one
dose of study medication; 429 received placebo, 419 were
treated with BEA2180 50 mg, 415 with BEA2180 100 mg, 390
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retention ratewas high and the total of 1862 (89.5%) patients
completed taking study medication according to the study
protocol (Fig. 1). The overall demographic profile, and
concomitant disease profile was similar between the treat-
ment groups. The mean (SD) age of patients was 64.2 (8.8)
years, 64.5% were male with a mean COPD duration of 8.4
years (Table 1a). All patients were either current (45.2%) or
ex-smokers (54.8%) with a mean smoking history of 47.5
pack-years. The COPD disease characteristics profile was
balanced across the treatment groups and consistent with
values expected for COPD patients.20 The mean baseline
prebronchodilator FEV1 was 1.2 L (43% of predicted value)
and postbronchodilator FEV1 was 1.3 L (49% of predicted
value) (Table 1b). There was no difference between
screening (1.2 L) and randomisation (1.2 L) FEV1 values. The
common mean baseline focal score was 6.5 and SGRQ total
score was 42.9. A total of 77.1% of patients were taking
respiratorymedication (s) at baseline, including: 11.7% long-
acting anticholinergics, 53.1% ICS and 56.3% LABAs; pulmo-
nary medication use was similar between treatment groups.
Lung function
The mean trough FEV1 at 24 weeks (primary efficacy
endpoint) was significantly greater (p < 0.0001) after
treatment with all three BEA2180 doses as well as after
treatment with tiotropium in comparison with placebo
(Fig. 2). The 50- and 100-mg doses reached statistical sig-
nificance compared with placebo but did not achieve non-
inferiority compared with tiotropium. The highest dose of
BEA2180, 200 mg, was shown to be noninferior to tiotropium
for the chosen margin (0.05 L).
Exacerbations
Compared with placebo, the risk of having a COPD exac-
erbation was significantly reduced for patients receivingFigure 1 CONSORT diagram illustrating the flow ofthe 50-mg or 200-mg dose of BEA2180 (hazard ratio [95%
confidence interval]: 0.65 [0.47, 0.91] and 0.72 [0.51,
1.00], respectively (Fig. 3). No significant difference from
placebo was observed for patients receiving the 100-mg
dose of BEA2180 or tiotropium 5 mg. In comparison with
tiotropium, no significant differences were observed for all
doses of BEA2180.
TDI
The TDI focal scores were significantly higher (p  0.01) for
patients receiving active medication (tiotropium or
BEA2180) versus patients receiving placebo over weeks 4,
12 and 24 (Fig. 4). No significant differences between tio-
tropium and BEA2180 doses were observed at either time
point.
SGRQ
The means for SGRQ total score were significantly lower
(p < 0.01) for patients receiving active medication (tio-
tropium or BEA2180) versus patients receiving placebo over
weeks 12e24 (Fig. 5). No significant differences in SGRQ
total score were found for the comparisons between tio-
tropium and any of BEA2180 doses.
Safety
The frequency of reported AEs was similar across all
treatment groups, with a total of 1274 (61.3%) patients
reporting any event. Adverse events were reported in 62.8%
of patients treated with BEA2180 50 mg, in 59.0% receiving
BEA2180 100 mg, and 64.4% treated with BEA2180 200 mg. Of
those receiving tiotropium 5 mg or placebo, 59.5% and
60.8%, respectively, experienced AEs (Table 2). The most
common AEs, reported in >3% of patients, included COPD
exacerbation (332 [16%]), nasopharyngitis (153 [7.4%]),
upper respiratory tract infection (99 [4.8%]), dyspnoea (78
[3.8%]) and cough (75 [3.6%]). COPD exacerbation was re-
ported in 13.6e15.9% of BEA2180-treated patients, 15.9% ofpatients through the study. FAS, full analysis set.
Table 1a Baseline characteristics.
Placebo BEA2180
50 mg
BEA2180
100 mg
BEA2180
200 mg
Tiotropium
5 mg
Total
Patients, N 429 419 415 390 427 2080
Male gender, N (%) 274 (63.9) 267 (63.7) 269 (64.8) 250 (64.1) 281 (65.8) 1341 (64.5)
Age, mean (SD), y 64.4 (8.6) 64.0 (8.7) 64.6 (9.1) 63.9 (8.9) 63.9 (8.7) 64.2 (8.8)
White race, N (%) 384 (89.5) 371 (88.5) 363 (87.5) 340 (87.2) 382 (89.5) 1840 (88.5)
BMI, mean (SD), kg/m2 27.2 (6.4) 26.9 (5.7) 27.1 (5.9) 27.5 (5.9) 26.8 (6.0) 27.1 (6.0)
Current smoker, N (%) 194 (45.2) 189 (45.1) 191 (46.0) 176 (45.1) 190 (44.5) 940 (45.2)
Ex-smoker, N (%) 235 (54.8) 230 (54.9) 224 (54.0) 214 (54.9) 237 (55.5) 1140 (54.8)
Smoking history, mean (SD),
pack-years
46.4 (22.0) 48.9 (27.6) 46.8 (23.9) 48.3 (26.8) 47.3 (24.9) 47.5 (25.1)
COPD duration, mean (SD), y 8.6 (6.6) 8.3 (6.4) 8.5 (6.4) 8.3 (6.7) 8.4 (6.5) 8.4 (6.5)
BMI, body mass index; COPD, chronic obstructive pulmonary disease; SD, standard deviation.
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treated patients (Table 2).
Drug-related AEs were reported in fewer than 10% of
patients overall (126 [6.1%]), and in 6.0% of those treated
with BEA2180 50 mg, in 5.3% receiving BEA2180 100 mg and in
8.7% of patients treated with BEA2180 200 mg. In the tio-
tropium 5 mg and placebo groups, 4.2% and 6.3% of patients,
respectively, experienced drug-related AEs. In order of
increasing frequency, the following drug-related AEs were
reported in 0.4e0.9% of all patients combined: COPD, tasteTable 1b Baseline spirometry.
Placebo BEA2180
50 mg
Patients, N 429 419
Before bronchodilation
FEV1, mean (SD), L 1.18 (0.46) 1.18 (0.46)
FEV1, mean (SD), % predicted 43.2 (14.5) 43.0 (14.8)
After bronchodilation
FEV1, mean (SD), L 1.34 (0.50) 1.34 (0.49)
FEV1, mean (SD), % predicted 49.1 (14.8) 49.0 (15.5)
FEV1 % change from
pre-bronchodilator value
15.5 16.0
BDI (focal score) 6.6 (2.0) 6.4 (2.1)
SGRQ total score, units 43.2 (18.1) 42.0 (17.5)
Respiratory medication, %
Any 74.6 77.3
Short-acting anticholinergics 27.7 28.9
Long-acting anticholinergics 11.9 11.7
SABAs 16.3 15.5
LABAs 54.6 58.0
ICS 52.0 53.0
LABA þ ICSa 35.0 36.0
Leukotriene receptor
antagonists
1.9 3.1
Oral steroids 3.0 2.2
Xanthines 14.0 14.1
Oxygen 4.2 2.4
BDI, Baseline Dyspnoea Index; FEV1, forced expiratory volume in 1 s;
short-acting b2-agonist; SD, standard deviation; SGRQ, St George’s Re
a Patients may have received more than one LABA þ ICS.disturbance, dyspnoea, cough and dry mouth. The inci-
dence of cough was highest with BEA2180 200 mg (1.5%) and
the incidence of dry mouth was highest with tiotropium
(1.6%).
More patients randomised to placebo (30 [7.0%]) re-
ported AEs that led to discontinuation of study medication
than those treated with BEA2180 50 mg (13 [3.1%]), 100 mg
(17 [4.1%]), 200 mg (29 [7.4%]) or tiotropium 5 mg (18
[4.2%]). More serious AEs were reported with placebo
(10.0%) than with any BEA2180 (8.0e9.2%) or tiotropiumBEA2180
100 mg
BEA2180
200 mg
Tiotropium
5 mg
Total
415 390 427 2080
1.18 (0.48) 1.19 (0.49) 1.20 (0.47) 1.18 (0.47)
43.5 (15.1) 43.5 (14.8) 43.2 (14.3) 43.3 (14.7)
1.33 (0.51) 1.36 (0.52) 1.35 (0.49) 1.34 (0.50)
48.9 (15.3) 49.8 (15.1) 48.6 (14.3) 49.1 (15.0)
14.9 16.7 15.0 15.6
6.5 (2.2) 6.4 (2.1) 6.5 (2.0) NA
43.0 (17.7) 44.0 (18.8) 43.1 (18.0) NA
76.1 78.7 78.7 77.1
28.4 33.1 30.4 29.7
11.8 10.5 12.4 11.7
13.3 18.5 16.6 16.0
54.9 56.9 56.9 56.3
51.8 53.1 55.5 53.1
37.3 39.2 36.8 36.8
2.7 4.4 1.9 2.7
3.9 2.8 1.6 2.7
13.5 17.2 16.4 15.0
3.9 3.9 3.0 3.5
ICS, inhaled corticosteroids; LABA, long-acting b2-agonist; SABA,
spiratory Questionnaire.
Figure 2 FEV1 trough BEA2180 (50, 100, 200 mg) versus placebo
and tiotropium (5 mg). Based on an ANCOVA with terms for base-
line, treatment, centre (centre random, all other effects fixed).
*p < 0.0001 compared with placebo. Number of patients;
þNoninferiority to tiotropium 5 mg, noninferiority deltaZ 0.05 L;
placebo (421), BEA2180 50 mg (417), BEA2180 100 mg (409),
BEA2180 200 mg (387), tiotropium 5 mg (423). Common baseline
mean (SE)Z 1.184 (0.010). ANCOVA,analysis of covariance; FEV1,
forced expiratory volume in 1 s; SE, standard error.
Figure 4 Adjustedmean TDI focal scores at 4, 12 and 24weeks
comparison to placebo and tiotropium. Based on ANCOVA with
terms for baseline, treatment, centre (centre random, all other
effects fixed). Number of patients: Placebo (406), BEA2180 50 mg
(410), BEA2180 100 mg (398), BEA2180 200 mg (379), tiotropium
5 mg (416). Common baseline mean (SE)Z 6.48 (0.05). *p 0.01
compared with placebo; ANCOVA, analysis of covariance; SE,
standard error; TDI, Transition Dyspnoea index.
BEA2180 versus placebo and tiotropium via Respimat SMI 859(8.2%) treatment. Among the BEA2180-treated patients,
serious AE frequencies were consistent across all dosing
groups. The proportion of serious AEs was comparable
among all treatments: among the 2080 patients, there were
20 fatal events; three randomised to BEA2180 50 mg, three
to BEA2180 100 mg, seven to BEA2180 200 mg, two to tio-
tropium 5 mg and five receiving placebo. In addition, two
patients died post-study; both were randomised to tio-
tropium. All cases were considered by the investigator to be
unrelated to study medication. Further details of AEs can
be found in the Online Supplement.
Discussion
This study was the first, long-term head-to-head compari-
son of the once-daily anticholinergic BEA2180 with the
once-daily tiotropium in patients with COPD. Both long-Figure 3 KaplaneMeier estimates of no COPD exacerbations,
BEA2180 (50, 100, 200 mg) versus tiotropium (5 mg) and pla-
cebo. COPD, chronic obstructive pulmonary disease.acting bronchodilators were inhaled via the Respimat SMI
delivery system.
Overall, in this trial of 2080 patients, both tiotropium
and BEA2180 were effective at improving lung function,
reducing the symptoms of COPD and were generally well
tolerated. The primary endpoint for this trial was achieved
and BEA2180 at all three doses was significantly better than
placebo with respect to FEV1 trough after 24 weeks of
treatment, although only the 200-mg dose of BEA2180 was
noninferior to tiotropium. There was no plateau in the
BEA2180 dose response curves at the studied doses and
results revealed that symptom assessments including SGRQ
and TDI were improved for all four active treatments versus
placebo, with little separation among treatment groups.
The prevention of exacerbations is a key component of
COPD management strategies,8 so it was a welcome finding
that COPD exacerbation yearly rates and time to first
exacerbation were numerically reduced in all active
treatments compared with placebo, reaching statistical
significance for the BEA2180 50- and 200-mg doses. The
observed effects of BEA2180 on exacerbations are surpris-
ing given the comparatively short duration of the trial,
which may explain the lack of an observed significant effect
of tiotropium on exacerbations. In this respect, the data
contrast with other studies of tiotropium, for example, the
Understanding Potential Long-term Impacts on Function
with Tiotropium (UPLIFT) study, carried out over a 4-year
period, demonstrated that tiotropium led to a reduction in
exacerbations amongst COPD patients compared with pla-
cebo.27 Similarly, data from a recent 48-week study
revealed that tiotropium reduced the time to first exacer-
bation and the time to first hospital-treated exacerbation
relative to placebo.3 Results from a patient-level pooled
analysis also confirmed that tiotropium reduced the risk of
exacerbations and associated hospitalisations compared
with placebo in randomised, placebo-controlled trials.10
Figure 5 Adjusted mean SGRQ total score comparison to
placebo and tiotropiumover 24weeks. Based on an ANCOVAwith
terms for baseline, treatment, centre (centre random, all other
effects fixed). Number of patients: Placebo (411), BEA2180 50 mg
(415), BEA2180 100 mg (404), BEA2180 200 mg (379), tiotropium
5 mg (419). Commonbaselinemean (SE)Z 42.87 (0.40). *p< 0.01
compared with placebo; ANCOVA, analysis of covariance; SE,
standard error; SGRQ, St George’s respiratory questionnaire.
Table 2 Summary of adverse events.
Placebo
N (%)
BEA21
50 mg
Number of patients 429 (100.0) 419 (1
Patients with any AE 261 (60.8) 263 (6
COPD 85 (19.8) 60 (1
Nasopharyngitisa 38 (8.9) 28 (6
Upper RTIa 20 (4.7) 26 (6
Dyspnoeaa 25 (5.8) 15 (3
Cougha 13 (3.0) 17 (4
Bronchitisa 10 (2.3) 16 (3
Headachea 7 (1.6) 9 (2
Sinusitisa 7 (1.6) 6 (1
Patients with severe AEs 39 (9.1) 33 (7
Patients with other significant AEs
(according to ICH E3)
18 (4.2) 5 (1
Patients with AEs leading to discontinuation
of trial drug
30 (7.0) 13 (3
Patients with serious AEs 43 (10.0) 37 (8
Fatal 5 (1.2) 3 (0
Immediately life threatening 0 (0.0) 1 (0
Disability/incapacitation 1 (0.2) 2 (0
Required hospitalisation 37 (8.6) 32 (7
Prolonged hospitalisation 3 (0.7) 3 (0
Congenital anomaly 0 (0.0) 0 (0
Other 5 (1.2) 3 (0
A patient may be counted in more than one seriousness criterion.
treatment as the denominator. Medical Dictionary for Regulatory Affa
AE, adverse event; COPD, chronic obstructive pulmonary disease; ICH,
infection.
a Preferred term.
860 R. Abrahams et al.Our study was not powered to detect differences in exac-
erbation rates; however, the efficacy data were compara-
ble for both compounds, suggesting BEA2180 might also
lead to reduced exacerbation rates in patients.
All active treatments were safe at the doses studied and
the overall safety profile of BEA2180 was consistent with
the patient population and with the known side-effect
profile of anticholinergics.9 None of the events leading to
death were considered to be related to study medication
and the causes of death were consistent with those ex-
pected in a patient population of >10 pack-year smokers.
Therapeutic delivery is a key concern of COPD mainte-
nance treatment, given issues of device use and compli-
ance.2,19 In many countries, tiotropium is administered via
the Respimat SMI, a novel propellant-free inhaler with a
soft-mist aerosol delivering fine-particle fraction. It gen-
erates a soft mist released over approximately 1.5 s, as
opposed to standard propellants.11 The low-cloud velocity
combined with <5 mm particle size, reduces oropharyngeal
deposition and allows for pervasive lung delivery,1 even
with poor inhalation technique.11 Previous studies have also
demonstrated significantly higher (p < 0.05) total satis-
faction scores for Respimat SMI compared with a dry-
powder and a metered-dose inhaler; in addition, more pa-
tients preferred and were willing to continue using the
Respimat SMI.12,21 The recommended dosage of two puffs
of tiotropium (2.5 mg per puff) once daily3 was the basis for
the dosage frequency used in the current trial. The main
strength of the trial is that it tested two compounds head to80
N (%)
BEA2180
100 mg N (%)
BEA2180
200 mg N (%)
Tiotropium
5 mg N (%)
Total N (%)
00.0) 415 (100.0) 390 (100.0) 427 (100.0) 2080 (100.0)
2.8) 245 (59.0) 251 (64.4) 254 (59.5) 1274 (61.3)
4.3) 66 (15.9) 53 (13.6) 68 (15.9) 332 (16.0)
.7) 33 (8.0) 27 (6.9) 27 (6.3) 153 (7.4)
.2) 21 (5.1) 13 (3.3) 19 (4.4) 99 (4.8)
.6) 14 (3.4) 11 (2.8) 13 (3.0) 78 (3.8)
.1) 17 (4.1) 18 (4.6) 10 (2.3) 75 (3.6)
.8) 11 (2.7) 10 (2.6) 12 (2.8) 59 (2.8)
.1) 9 (2.2) 11 (2.8) 16 (3.7) 52 (2.5)
.4) 7 (1.7) 13 (3.3) 10 (2.3) 43 (2.1)
.9) 30 (7.2) 34 (8.7) 25 (5.9) 161 (7.7)
.2) 13 (3.1) 16 (4.1) 14 (3.3) 66 (3.2)
.1) 17 (4.1) 29 (7.4) 18 (4.2) 107 (5.1)
.8) 33 (8.0) 36 (9.2) 35 (8.2) 184 (8.8)
.7) 3 (0.7) 7 (1.8) 2 (0.5) 20 (1.0)
.2) 0 (0.0) 3 (0.8) 0 (0.0) 4 (0.2)
.5) 1 (0.2) 2 (0.5) 0 (0.0) 6 (0.3)
.6) 30 (7.2) 30 (7.7) 32 (7.5) 161 (7.7)
.7) 1 (0.2) 3 (0.8) 0 (0.0) 10 (0.5)
.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
.7) 3 (0.7) 3 (0.8) 3 (0.7) 17 (0.8)
Percentages are calculated using total number of patients per
irs version12.0 used for reporting.
International Conference on Harmonisation; RTI, respiratory tract
BEA2180 versus placebo and tiotropium via Respimat SMI 861head, versus each other and placebo, using the same de-
livery system without differences in the in vitro aero-
dynamic particle size distributions. This design resulted in a
true comparison without the need for using a double
dummy, which could have negatively impacted the data for
a variety of reasons.11,21
A limitation of this study was that it was a single trial,
and there are currently no confirmatory data to support the
findings. The timeframe and sample size may have been
insufficient to enable the true clinical impact of tiotropium
and BEA2180 on exacerbations; it is possible that a longer
study might have given a more representative result for
both. A short trial duration may also explain why we found
significance for exacerbation reduction in 50- and 200-mg,
but not in the 100-mg treatment arm; this discrepancy be-
tween the low, high and intermediate dose is difficult to
interpret, and may reflect borderline data, or alternatively
a statistical artefact. However, all active treatments
showed a positive numerical trend, suggesting the effect of
BEA2180 might be similar to tiotropium. Longer trials,
powered to further evaluate the effect of BEA2180 on
exacerbation rates, are required before more solid con-
clusions can be drawn.
There are several other avenues that future studies
might explore; one particular aspect of importance is pa-
tient acceptance of therapy, as adherence to a prescribed
regimen is clearly vital in the management of COPD as a
long-term, chronic condition.4 Rapid onset and long dura-
tion of action are similarly important issues to patients7,26
as earlier relief of symptoms helps improve compliance
and has a direct impact on quality of life in patients with
COPD.25 TIOSPIR, a large scale, prospective, randomised
trial comparing tiotropium SMI 5 mg, 2.5 mg and HandiHaler
18 mg in >17,000 patients was initiated by Boehringer
Ingelheim in 2009. The study is due to end in 2013 and was
designed to elucidate the all-cause mortality risks associ-
ated with tiotropium SMI 5 mg. In the present study, there
were numerically fewer fatal adverse events in the tio-
tropium group (2 vs 5 for placebo).
Conclusions
The long-acting anticholinergic bronchodilators, BEA2180
and tiotropium, both delivered via Respimat SMI, were
effective at improving lung function and reducing the
symptoms of COPD. Only the 200-mg dose of BEA2180 was
comparable to tiotropium with respect to FEV1 trough. The
risk of COPD exacerbations was reduced with all active
treatments, reaching statistical significance for BEA2180
50 and 200 mg. Overall, the safety profile of both trial
drugs was consistent with the patient population and with
the known anticholinergic side-effect profile. All active
treatments were well tolerated at the doses studied in
this trial.
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